Cancer Pain Single Nucleotide Polymorphisms (SNPs)

This study has been completed.
Information provided by (Responsible Party):
Joost LM Jongen, Erasmus Medical Center Identifier:
First received: August 10, 2009
Last updated: December 23, 2014
Last verified: December 2014
Cancer pain is common in advanced cancer patients. Opioids are the mainstay of treatment in cancer pain. Responsiveness to and tolerability of opioids is, amongst others, determined by small variations in human DNA. Using blood samples from clinically well-defined cancer pain patients, the investigators are going to analyze single nucleotide polymorphisms (SNPs) in genes that are known to be involved in responsiveness to opioids and sensitivity to pain.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Storage and Analysis of Patient Blood-samples for Cancer Pain Research

Resource links provided by NLM:

Further study details as provided by Erasmus Medical Center:

Primary Outcome Measures:
  • correlation between pain SNPs and equianalgesic opioid requirement [ Time Frame: timepoint at blood sample ] [ Designated as safety issue: No ]
    candidate SNP analysis

Biospecimen Retention:   Samples With DNA
Whole Blood

Enrollment: 243
Study Start Date: September 2008
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Cancer Pain Patients


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Cancer pain patients in a large university hospital

Inclusion Criteria:

  • Cancer pain patients

Exclusion Criteria:

  • Patients not able to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00956878

Erasmus MC, Centrumlocatie en Daniel den Hoed
Rotterdam, Zuid-Holland, Netherlands, 3000CA
Sponsors and Collaborators
Erasmus Medical Center
Principal Investigator: Joost L Jongen, MD PhD Erasmus MC
  More Information

Additional Information:
No publications provided

Responsible Party: Joost LM Jongen, Dr. J.L.M. Jongen, MD, PhD, Erasmus Medical Center Identifier: NCT00956878     History of Changes
Other Study ID Numbers: MEC2008-166
Study First Received: August 10, 2009
Last Updated: December 23, 2014
Health Authority: Netherlands: Dutch Health Care Inspectorate

Keywords provided by Erasmus Medical Center:
SNP processed this record on November 30, 2015